Related Experiment Video
Updated: Aug 14, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Active stents in diabetic patients
1Laboratoire d'hémodynamique et cardiologie interventionelle, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpétrière, Paris, France. gerard.drobinski@psl.ap-hop-paris.fr
Diabetes & Metabolism
|December 22, 2005
Summary
Drug-eluting stents significantly reduce restenosis in diabetic patients undergoing percutaneous coronary intervention (PCI). Studies show lower rates of restenosis and target lesion revascularization compared to traditional stents, improving long-term outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Background:
- Diabetic patients historically experience poorer outcomes after percutaneous coronary intervention (PCI) for coronary stenosis compared to non-diabetics.
- Restenosis has been a significant challenge, particularly in diabetic populations undergoing PCI.
Purpose of the Study:
- To evaluate the efficacy of drug-eluting stents (DES) in improving outcomes for diabetic patients with coronary stenosis.
- To compare restenosis and target lesion revascularization rates between DES and bare-metal stents (BMS) in diabetic patients.
Main Methods:
- Analysis of data from large clinical studies including RAVEL, SIRIUS, TAXUS IV, and TAXUS VI.
- Comparison of restenosis rates and target lesion revascularization (TLR) in diabetic patients treated with sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), and BMS.
Main Results:
- Sirolimus-eluting stents demonstrated 0% restenosis in the RAVEL study and significantly reduced restenosis (17.6% vs. 50.5%) and TLR (6.9% vs. 22.3%) in the SIRIUS study compared to BMS.
- Paclitaxel-eluting stents showed an 80-82% reduction in restenosis in the TAXUS IV study and a significantly lower TLR rate (2.6% vs. 22.6%) in the TAXUS VI study.
- Overall, DES significantly improved long-term results for diabetic patients compared to historical data.
Conclusions:
- Drug-eluting stents, particularly those with sirolimus or paclitaxel, offer substantial benefits for diabetic patients undergoing PCI for coronary stenosis.
- DES effectively mitigate the increased risk of restenosis and target lesion revascularization in diabetic patients, leading to improved long-term outcomes.
Related Concept Videos
01:31Diabetic Foot Ulcer
Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:23Peripheral Artery Disease V: Postoperative Nursing Management
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...